Additional file 1 of A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

MLA

Chan, Stephen L., et al. Additional File 1 of A First-in-Human Phase 1/2 Study of FGF401 and Combination of FGF401 with Spartalizumab in Patients with Hepatocellular Carcinoma or Biomarker-Selected Solid Tumors. Jan. 2022. EBSCOhost, https://doi.org/10.6084/m9.figshare.19980537.

APA

Chan, S. L., Schuler, M., Kang, Y.-K., Yen, C.-J., Edeline, J., Choo, S. P., Lin, C.-C., Okusaka, T., Weiss, K.-H., Macarulla, T., Cattan, S., Blanc, J.-F., Lee, K.-H., Maur, M., Pant, S., Kudo, M., Assenat, E., Zhu, A. X., Yau, T., … Delord, J.-P. (2022). Additional file 1 of A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. https://doi.org/10.6084/m9.figshare.19980537

Chicago

Chan, Stephen L., Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo, Chia-Chi Lin, et al. 2022. “Additional File 1 of A First-in-Human Phase 1/2 Study of FGF401 and Combination of FGF401 with Spartalizumab in Patients with Hepatocellular Carcinoma or Biomarker-Selected Solid Tumors,” January. doi:10.6084/m9.figshare.19980537.